Table 2.
Mean percentages of CD19+, CD4+ andCD8+ cells expressing Tim-3, PD-1, and CCR5 among groups
| Cells | HCV–HCC patients (n = 40) |
Controls (n = 40) |
p value |
|---|---|---|---|
| Tim-3+ CD19+ (%) | 1.3 ± 0.01 | 1.2 ± 0.01 | 0.2 |
| Tim-3+ CD4+ (%) | 8.9 ± 0.5 | 4 ± 0.3 | < 0.0001 |
| Tim-3+ CD8+ (%) | 10.4 ± 1 | 5.5 ± 0.2 | < 0.0001 |
| PD-1+CD19+ (%) | 23 ± 0.5 | 17.2 ± 0.5 | < 0.0001 |
| PD-1+CD4+ (%) | 20.3 ± 0.4 | 15.2 ± 0.4 | < 0.0001 |
| PD-1+CD8+ (%) | 30.9 ± 1 | 21.1 ± 0.4 | < 0.0001 |
| CCR5+CD19+ (%) | 10.6 ± 0.4 | 11.5 ± 0.5 | 0.1 |
| CCR5+CD4+ (%) | 10.6 ± 0.6 | 15.1 ± 0.9 | < 0.0001 |
| CCR5+CD8+ (%) | 20 ± 0.3 | 22.5 ± 0.5 | < 0.0001 |
n number, HCV–HCC hepatitis C related hepatocellular carcinoma
Results expressed as mean percentages ± SE
Independent T Test, bold p values indicate significance (< 0.05)